CN112996776A - 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 - Google Patents

6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN112996776A
CN112996776A CN202080005987.XA CN202080005987A CN112996776A CN 112996776 A CN112996776 A CN 112996776A CN 202080005987 A CN202080005987 A CN 202080005987A CN 112996776 A CN112996776 A CN 112996776A
Authority
CN
China
Prior art keywords
group
compound
pharmaceutically acceptable
alkyl
mesomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080005987.XA
Other languages
English (en)
Other versions
CN112996776B (zh
Inventor
杨方龙
郁楠
池江涛
刘志伟
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Shengdi Pharmaceutical Co ltd
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112996776A publication Critical patent/CN112996776A/zh
Application granted granted Critical
Publication of CN112996776B publication Critical patent/CN112996776B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种通式(I)所示的6‑氧代‑1,6‑二氢哒嗪类前药衍生物、其制备方法及含有该衍生物的药物组合物，以及其作为NaV抑制剂的用途和其在制备治疗和/或预防疼痛和疼痛相关疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080005987.XA 2019-02-20 2020-02-19 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 Active CN112996776B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2019101257504 2019-02-20
CN201910125750 2019-02-20
CN201910384992 2019-05-09
CN2019103849925 2019-05-09
CN2019105670356 2019-06-27
CN201910567035 2019-06-27
CN2020100208630 2020-01-09
CN202010020863 2020-01-09
PCT/CN2020/075790 WO2020169042A1 (zh) 2019-02-20 2020-02-19 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN112996776A true CN112996776A (zh) 2021-06-18
CN112996776B CN112996776B (zh) 2024-03-15

Family

ID=72144157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080005987.XA Active CN112996776B (zh) 2019-02-20 2020-02-19 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用

Country Status (12)

Country Link
US (1) US20220162169A1 (zh)
EP (1) EP3929181A4 (zh)
JP (1) JP2022521483A (zh)
KR (1) KR20210131357A (zh)
CN (1) CN112996776B (zh)
AU (1) AU2020224245A1 (zh)
BR (1) BR112021014178A2 (zh)
CA (1) CA3129600A1 (zh)
MX (1) MX2021009539A (zh)
TW (1) TW202102480A (zh)
WO (1) WO2020169042A1 (zh)
ZA (1) ZA202106711B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112500353A (zh) * 2020-12-08 2021-03-16 北京晨光同创医药研究院有限公司 一种左西孟旦的前药化合物、制备方法及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202214259A (zh) * 2020-08-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種選擇性ＮａＶ抑制劑的前藥及其晶型
TW202220962A (zh) * 2020-08-19 2022-06-01 大陸商江蘇恒瑞醫藥股份有限公司 選擇性NaV抑制劑的結晶形式及其製備方法
CN116964065A (zh) * 2021-02-26 2023-10-27 江苏恒瑞医药股份有限公司 一种选择性NaV抑制剂的可药用盐、结晶形式及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101238109A (zh) * 2005-06-09 2008-08-06 沃泰克斯药物股份有限公司 作为离子通道调节剂的茚满衍生物
WO2014209094A1 (fr) * 2013-06-27 2014-12-31 Universite Mohammed V Souissi Dérivés de pyridazin-3(2h)-one, préparation, activités pharmacologiques et biologiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35288A (es) * 2013-01-31 2014-08-29 Vertex Pharma Piridonamidas como moduladores de canales de sodio
AP2016009287A0 (en) * 2013-12-13 2016-06-30 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
WO2016004417A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101238109A (zh) * 2005-06-09 2008-08-06 沃泰克斯药物股份有限公司 作为离子通道调节剂的茚满衍生物
WO2014209094A1 (fr) * 2013-06-27 2014-12-31 Universite Mohammed V Souissi Dérivés de pyridazin-3(2h)-one, préparation, activités pharmacologiques et biologiques

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112500353A (zh) * 2020-12-08 2021-03-16 北京晨光同创医药研究院有限公司 一种左西孟旦的前药化合物、制备方法及其应用
CN112500353B (zh) * 2020-12-08 2022-11-25 北京晨光同创医药研究院有限公司 一种左西孟旦的前药化合物、制备方法及其应用

Also Published As

Publication number Publication date
MX2021009539A (es) 2021-11-04
CA3129600A1 (en) 2020-08-27
AU2020224245A1 (en) 2021-08-05
TW202102480A (zh) 2021-01-16
US20220162169A1 (en) 2022-05-26
WO2020169042A1 (zh) 2020-08-27
EP3929181A4 (en) 2022-10-26
BR112021014178A2 (pt) 2021-09-21
EP3929181A1 (en) 2021-12-29
ZA202106711B (en) 2022-08-31
JP2022521483A (ja) 2022-04-08
CN112996776B (zh) 2024-03-15
KR20210131357A (ko) 2021-11-02

Similar Documents

Publication Publication Date Title
CN112955436B (zh) 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
CN112996774B (zh) 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112996776B (zh) 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
TW202115038A (zh) 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
WO2021197464A1 (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022037641A1 (zh) 一种选择性NaV抑制剂的前药及其晶型
WO2020238791A1 (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
RU2694899C2 (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
BR112014016648B1 (pt) derivados policíclicos, seus usos e seu processo de preparação, e composição farmacêutica
WO2021121210A1 (zh) 并环类衍生物、其制备方法及其在医药上的应用
WO2020253762A1 (zh) 吲唑类衍生物、其制备方法及其在医药上的应用
CN115594695A (zh) 大环类化合物、其制备方法及其在医药上的应用
WO2022111498A1 (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2022002243A1 (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
TW202144342A (zh) 芳甲醯胺類化合物及其製備方法和醫藥用途
TW202114989A (zh) 吡啶苯甲醯胺類衍生物、其製備方法及其在醫藥上的應用
RU2791534C2 (ru) Производное 6-оксо-1,6-дигидропиридазина, способ его получения и его применение в медицине
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
WO2022068915A1 (zh) 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051454

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20220630

Address after: 361026 room 53, floor 1, building A19, Xiamen biomedical industrial park, 2036 wengjiao West Road, Haicang District, Xiamen City, Fujian Province

Applicant after: Fujian Shengdi Pharmaceutical Co.,Ltd.

Applicant after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Applicant after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Applicant before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Applicant before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant